Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175452 | 0.89 | MEN1 (0.36) | MEN1KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL1685013 | 0.89 | MEN1 (0.36) | MEN1KMT2AALDH1A1LMNAPOLB | |
| SCHEMBL729742 | 0.85 | MEN1 (0.37) | MEN1KMT2APRMT1F2ST14 | |
| SCHEMBL727316 | 0.85 | MEN1 (0.37) | MEN1KMT2APRMT1F2ST14 | |
| SCHEMBL729234 | 0.84 | MEN1 (0.38) | MEN1KMT2AALDH1A1PRMT1F2 | |
| SCHEMBL727965 | 0.83 | PRMT1 (0.53) | PRMT1F2ST14PLAUPLG | |
| Hydrochloric Acid SCHEMBL3241146 | 0.82 | PRSS1 (0.54) | PRMT1F2ST14PLAUPLG | |
| SCHEMBL727594 | 0.82 | MEN1 (0.38) | MEN1KMT2AALDH1A1PLAUPLG | |
| SCHEMBL3192337 | 0.82 | PRSS1 (0.52) | PRMT1F2ST14PLAUPLG | |
| SCHEMBL3469347 | 0.81 | HDAC1 (0.45) | MEN1KMT2AHRH3RARBPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242152-B2 | Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for the prophylaxis and treatment of osteoporosis | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2012-08-14 | — | — | US | claimed |
| EP-1411935-B1 | USE OF 4- (4-THIAZOLYL)PHENOXL ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS | DONG WHA PHARM CO LTD (KR) | 2010-05-19 | — | — | EP | claimed |
| US-7662840-B2 | 4-{5-[4-(5-Isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine (DW-1350); a leukotriene-B4 receptor antangonist; inhibiting osteoclastic bone absorption | DONG WHA PHARMACEUTICAL CO., LTD. (KR) | 2010-02-16 | — | — | US | claimed |
| EP-1411935-A4 | USE OF 4- (4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS | DONG WHA PHARM IND CO LTD (KR) | 2005-11-09 | — | — | EP | claimed |
| US-20040186150-A1 | Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis | DONG WHA PHARMACEUTICAL CO., LTD. (KP) | 2004-09-23 | — | — | US | claimed |
| EP-1411935-A1 | USE OF 4- (4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS | DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) | 2004-04-28 | — | — | EP | claimed |
| WO-2003007947-A1 | USE OF 4-[(4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS | DONG WHA PHARM. IND. CO., LTD. (KR) | 2003-01-30 | — | — | WO | claimed |
| EP-1701722-B1 | N-HYDROXY-4-{5-[4-(5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL)PHENOXY¨]PENTOXY}BENZAMIDINE 2 METHANSULFONIC ACID SALT | DONG WHA PHARM CO LTD (KR) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186150-A1 | Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis | LTB4R, LTB4R2, CYSLTR1 | MEN1 2817/4885KMT2A 1535/4885ALDH1A1 1962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.